Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Donepezil Hydrochloride NDC 68071-1572 by Nucare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Structural Formula - 41d7651e b91a 4118 8719 bf2f663d82a2 01
Figure 1 - 41d7651e b91a 4118 8719 bf2f663d82a2 02
This text appears to be a table or graph with information on ADAS-cog change from baseline and the clinical improvement of different drug treatments. The treatments mentioned are Donepezil hydrochloride at 10mg per day, Donepezil hydrochloride at 5mg per day, and placebo. The table also includes information on weeks of drug treatment and the percentage of change. Without more context or a clearer image, it is difficult to provide a more detailed description.*
Figure 2 - 41d7651e b91a 4118 8719 bf2f663d82a2 03
The text represents a graph that shows the cumulative percentage of patents who showed a change in ADAS-cog score and the difference between Placebo and Donepezil hydrochloride at 5 mg/day and 10 mg/day doses. The graph indicates that the higher the dose, the higher the percentage of patents who showed a positive change in ADAS-cog score. The y-axis represents the percentage of patients, and the x-axis represents the change in ADAS-cog score. The text is best understood when accompanied by the actual graph.*
Figure 3 - 41d7651e b91a 4118 8719 bf2f663d82a2 04
Figure 4 - 41d7651e b91a 4118 8719 bf2f663d82a2 05
This is a clinical study comparing the effect of Donepezil hydrochloride at two different doses (5 mg/day and 10 mg/day) versus a placebo. The evaluation was done by measuring the ADAS-cog change from baseline (initial evaluation) after several weeks of drug treatment. The text is not very clear, but it suggests that the results showed some level of clinical improvement in the group that received Donepezil hydrochloride, compared to the placebo group.*
Figure 5 - 41d7651e b91a 4118 8719 bf2f663d82a2 06
Figure 6 - 41d7651e b91a 4118 8719 bf2f663d82a2 07
This is a table displaying the percentage of patients who took either Aricept 10 mg/day, Aricept 5mg/day, or a placebo. The table measures the improvement in CIBIC-plus ratings with categories ranging from markedly improved to worse.*
Figure 7 - 41d7651e b91a 4118 8719 bf2f663d82a2 08
Figure 8 - 41d7651e b91a 4118 8719 bf2f663d82a2 09
This is a clinical trial study comparing donepezil hydrochloride to a placebo. The daily dose of donepezil is 10 mg. The text includes a graph labeled as "Change from Baseline". The remaining text is not readable.*
Figure 9 - 41d7651e b91a 4118 8719 bf2f663d82a2 10
Figure 10 - 41d7651e b91a 4118 8719 bf2f663d82a2 11
68071 1572 9
This is a medication label for Donepezil HCI 5mg tablets. It contains information including lot number, manufacturer, expiration date, and dosage instructions. It also provides warnings about potential side effects and advises to store at a controlled temperature.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.